NCT05124509View on ClinicalTrials.gov

Immune Response to Third Dose of COVID-19 Vaccine in Solid Organ Transplant

CompletedOBSERVATIONAL
Enrollment

147

Participants

Timeline

Start Date

October 6, 2021

Primary Completion Date

December 13, 2021

Study Completion Date

January 3, 2022

Conditions
COVID-19SARS-CoV-2 InfectionSolid Organ TransplantVaccine Response Impaired
Interventions
BIOLOGICAL

Three doses of SARS-CoV-2 BNT162b2 vaccine (observational)

Two doses of SARS-CoV-2 BNT162b2 mRNA vaccine, followed by a booster (3rd) dose of SARS-CoV-2 BNT162b2 mRNA vaccine.

BIOLOGICAL

Two doses of CoronaVac and one dose of BNT162b2 SARS-CoV-2 vaccine (observational)

Two doses of CoronaVac SARS-CoV-2 inactivated vaccine, followed by a booster (3rd) dose of BNT162b2 mRNA vaccine.

Trial Locations (1)

Unknown

Pontificia Universidad Católica de Chile, Santiago

All Listed Sponsors
lead

Pontificia Universidad Catolica de Chile

OTHER

NCT05124509 - Immune Response to Third Dose of COVID-19 Vaccine in Solid Organ Transplant | Biotech Hunter | Biotech Hunter